Introduction {#S0001}
============

Hepatocellular carcinoma (HCC) accounting for 70--85% of the primary tumors of the liver is one of the highest mortality tumors all over the world.[@CIT0001] The improvement in HCC treatment including liver resection, chemotherapy and transplantation has improved 5-year survival rates.[@CIT0002] However, survival rates of the HCC patients diagnosed in late stage remain extremely low.[@CIT0003] Therefore, development of novel and helpful early detection approaches is urgently needed for improving the therapeutic efficiency for HCC.

The Spalt-Like Transcription Factor 4 (Sall4) oncogene plays a central function in embryo-fetal development and is absent in differentiated tissues.[@CIT0004] Reexpression of Sall4 in HCC tissues involved in demethylation of its CpGs is associated with poor prognosis.[@CIT0005],[@CIT0006] In addition, 1 week after treatment, higher levels of Sall4 protein in serum were observed in HCC patients, and these patients had poor prognosis evidenced by high tumor recurrence and low overall survival rate.[@CIT0007] Thus, reexpression of Sall4 is relevant to the poor prognosis of HCC patients. Activation of WNT/β-catenin signaling that was positively correlated with Sall4 has been described as a crucial regulator in tumorgenesis.[@CIT0008] Constitutive expression of Sall4 causes myelodysplastic syndrome)/acute myeloid leukemia through the Wnt/beta-catenin pathway.[@CIT0009] In esophageal squamous cell carcinoma (ESCC), silencing of Sall4 inhibited tumor formation in vivo via Wnt/β-catenin signaling pathway.[@CIT0010] And Sall4 promotes intrahepatic cholangiocarcinoma cell proliferation through Wnt/β-catenin signaling and enhancing epithelial--mesenchymal transition (EMT) process.[@CIT0011] Thus, these studies proposed that Sall4/Wnt/β-catenin signaling may be a potentially promising molecular signaling for guiding HCC diagnosis and treatment.

Contrast-enhanced ultrasonography (CEUS), a typical nontraumatic examination method providing blood perfusion parameters, has been widely applied for diagnosis of many human cancers, including breast cancer and liver cancer.[@CIT0012] Abundant new vessel generates around the tumors. CEUS is able to accurately and clearly show the characteristics of angiogenesis and neovessels in liver tumors and parenchyma.[@CIT0013]

Thus, in this study, we aim to investigate the association between the quantitative parameters of CEUS and Sall4/Wnt/β-catenin pathway in early diagnosis of HCC.

Patients and methods {#S0002}
====================

Clinical patients recruitment {#S0002-S2001}
-----------------------------

One hundred and sixty-eight patients diagnosed as HCC without diabetes, cardiovascular disease and other tumors from February 2011 to December 2011 in the General Hospital of Ningxia Medical University were included. The age ranged from 20 to 76 years (median is 52 years). The follow-up of all the patients was completed. The clinical information is shown in [Table 1](#T0001){ref-type="table"}. The HCC tissues and adjacent tissues were obtained from surgical section and stored at liquid nitrogen until use. The tumor cells were confirmed by H&E staining. All subjects provided written informed consent. This study was approved by the Ethics Committee of General Hospital of Ningxia Medical University and was conducted in accordance with the Declaration of Helsinki.Table 1Clinicopathological features of 168 patients with hepatocellular carcinomaFeatureCase numberGender (male/female)108/60Alcohol history (yes/no)110/58Tumor differentiation (high/moderate/low differentiation)74/52/42TMN stage (I/II/III/IV)36/24/47/61Tumor size (\<3 cm/≥3 cm)75/93Vascular invasion (yes/no)97/71Lymphatic invasion (yes/no)101/67Liver cirrhosis (yes/no)106/62AFP (\<20/≥20 ng/mL)50/118HBsAg/HCV (negative/positive)110/58HBV-DNA(negative/positive)70/98[^1]

Medical records of patients were collected. All patients who underwent tumor resection were followed up. The clinical features and postoperative symptoms were recorded. The CEUS was performed every 3 months after the surgery to evaluate the liver function. The follow-up started from the end of the surgery and lasted until December 2016. The survival time was defined as from the first day in hospital to the date of death with any reasons. The time of disease-free survival (DFS) was defined as until a tumor recurrence and/or metastatic lesions were observed. The DFS rates (1-, 3- or 5-year) were recorded.

CEUS {#S0002-S2002}
----

The patients were routinely examined with iU22 ultrasonic inspection instrument (Royal Philips Electronics NV, Eindhoven, the Netherlands) according to the standard operating procedure. All CEUS were performed and evaluated by two sonographers with more than 3 years' experience in CEUS. Both low-frequency and high-frequency probe were used for CEUS. All patients received an intravenous injection of 2.4 mL of SonoVue, followed by 5 mL of saline flush. There was an interval of 10 mins between the two examinations in every patient. Four mins after contrast agent administration, CEUS process was recorded for 180 s to observe the lesions. The following CEUS patterns of nodules were considered: extent of enhancement during the arterial phase. The dynamic image was recorded on the hard disk of the sonography machine. Qlab software was used to analyze the microvessel image. The peak intensity (PI), area under the curve (AUC), blood perfusion time--intensity curve, time to peak (TTP) and washout time (WOT) were recorded for analysis.

Immunohistochemical staining assay {#S0002-S2003}
----------------------------------

Immunohistochemical staining was used to determine the expression of Sall4, WNT3a and β-catenin. Briefly, the tissue sections cut at 4 μm were deparaffinized and hydrated, and then were retrieved with citrate buffer at boiling water for 15 mins. Then, the sections were incubated with primary antibodies (mouse monoclonal anti-Sall4, 1:200, mouse monoclonal anti- WNT3a, 1:300, rabbit polyclonal anti-β-catenin, 1:200, Cell Signal Technology, Danvers, MA, USA) overnight at 4°C. The sections were then incubated with secondary antibody for 60 mins at 37°C. The signaling was visualized by diaminobenzidine (DAB) and counterstained with hematoxylin.

For evaluating the expression of Sall4, WNT3a and β-catenin, the integral optical density (IOD) was obtained by ImageJ (National Institutes of Health, Bethesda, MA, USA). The IOD of Sall4, WNT3a and β-catenin expression was normalized to the average IOD of them in normal tissues.

RNA extraction and quantitative PCR analysis {#S0002-S2004}
--------------------------------------------

Total RNA was extracted from cells using trizol reagent (Invitrogen, Carlsbad, CA, USA). Sall4, WNT3a and β-catenin mRNA expression was measured by SYBR green qPCR assay (Takara, Dalian, China) according to the recommended protocol. Expression of β-actin was used as an endogenous control. The primers were used as follows: Sall4, sense, CTAGACACGGCTCCCAATGC, antisense, AGACGTGA-ACTGCCCGAATC; WNT3a, sense, CTGGAGCTAGTGT-CTCCTCTCT, antisense, GGAAGAAGCCTCATCCAC-CA; β-catenin, sense, ATAAGAGCTCCTTGTGCGGC, antisense, GGCCATGTCCAACTCCATCA; β-actin, sense, AGGGGCCGGACTCGTCATACT, antisense, GGCGGCA-CCACCATGTACCCT. q-PCR was performed at the condition: 95.0°C for 3 mins and 39 circles of 95.0°C for 10 s and 60°C for 30 s. Data were processed using 2^−ΔΔCT^ method.

Statistical analysis {#S0002-S2005}
--------------------

SPSS17.0 statistical software (SPSS Inc. Chicago, IL, USA) was used to analyze the data. The data were presented as mean ± SD. The clinical association between protein expression, quantitative parameters of CEUS and clinicopathological variables in HCC patients was evaluated by Chi-square test. The difference among the groups was analyzed by Student's *t*-test or one-way ANOVA depending on the conditions. And multivariate survival analysis was performed using Cox proportional hazards model. *P*-value \<0.05 was considered to be statistically significant.

Results {#S0003}
=======

The expression of Sall4, WNT3a and β-catenin in HCC and adjacent tissues {#S0003-S2001}
------------------------------------------------------------------------

Sall4 was expressed in the nucleus, and WNT3a and β-catenin were expressed in the cytoplasm. The expressions of Sall4, WNT3a and β-catenin in the HCC tissues evaluated by IHC were significantly upregulated compared with the adjacent tissues ([Figure 1](#F0001){ref-type="fig"}). The mRNA levels of Sall4, WNT3a and β-catenin were measured by q-PCR. In line with the findings of immunochemistry, the results revealed that Sall4, WNT3a and β-catenin mRNA levels were higher in the HCC tissues than those in the adjacent tissues ([Figure 2](#F0002){ref-type="fig"}, all *P*\<0.05).Figure 1The representative IHC staining of Sall4, WNT3a and β-catenin in the HCC and adjacent normal tissues, and semiquantification. Scale bar, 100 μm. \**P*\<0.05 vs adjacent control.**Abbreviations:** HCC, hepatocellular carcinoma; IHC, immunohistochemistry; Sall4, Spalt-Like Transcription Factor 4.Figure 2The Sall4, WNT3a and β-catenin mRNA expressions in HCC and adjacent normal tissues; \**P*\<0.05 vs adjacent control.**Abbreviations:** HCC, hepatocellular carcinoma; Sall4, Spalt-Like Transcription Factor 4.

Alterations of the parameters of CEUS in liver parenchyma and HCC tissues {#S0003-S2002}
-------------------------------------------------------------------------

Angiogenesis in HCC was enhanced compared with the liver parenchyma. We analyzed of the blood perfusion time--intensity curve and found that the TTP and WOT of CEUS in the HCC were significantly decreased, whereas PI and AUC of CEUS in HCC were dramatically increased than in the liver parenchyma (all *P*\<0.05, [Table 2](#T0002){ref-type="table"}).Table 2Comparisons of quantitative parameters of CEUS between liver parenchyma and HCC lesionsTissuesTime to peak (s)Peak intensity (dB)Area under the curve (dB\*s)Washout time (s)HCC lesions23.45±4.31\*68.76±13.23\*1,562.50±211.20\*42.76±7.43\*Liver parenchyma35.02±5.4146.42±5.76776.67±77.8684.54±18.41[^2][^3]

Associations between Sall4, WNT3a and β-catenin expression and clinicopathological features of HCC patients {#S0003-S2003}
-----------------------------------------------------------------------------------------------------------

The expression of Sall4, WNT3a and β-catenin was not associated with age, gender and smoking history (*P*\>0.05), but associated with tumor differentiation, TNM stage, tumor size, vascular invasion and liver cirrhosis of HCC patients (*P*\<0.05). However, the positive rates of these proteins had no significant difference among viral cirrhosis, alcohol cirrhosis and other types of cirrhosis. In addition, Sall4 expression was significantly associated with HBV, HCV and alcohol history (*P*\<0.05), whereas WNT3a and β-catenin expression was not associated with these features (*P*\>0.05) ([Table 3](#T0003){ref-type="table"}).Table 3Association of Sall4, WNT3a and β-catenin protein expressions with clinicopathological features of HCC patientsFeatureSall4 expression (%)*P*-valueWNT3a expression (%)*P*-valueβ-catenin expression (%)*P*-valueAge (years)0.4670.6430.874\<5076.3356.3866.76≥5083.4563.4170.34Gender0.7530.8640.647Male78.3258.5167.39Female80.2162.3572.57Tumor differentiation0.0430.0420.031Low72.7562.8258.56Moderate76.5667.3565.42High86.2170.3173.11TNM stage0.0050.0370.015I+II65.3455.8756.42III+IV89.7569.4775.46Tumor size0.0130.0250.024 \<3 cm68.7254.3658.23 ≥3 cm87.3470.2674.43Vascular invasion0.0010.0310.006Yes88.1269.6476.26No63.3156.1853.18Liver cirrhosis0.0420.0460.038Yes79.8468.7969.44No70.5352.6457.58HCV infection0.0340.5720.635Positive45.6349.4244.37Negative28.7432.3738.71HBV infection0.0280.0920.078Positive48.7660.2168.35Negative23.5754.8559.46Alcohol history0.00010.0610.078Yes90.4265.7270.25No50.4356.8464.93Smoking history0.0930.2430.237Yes81.3262.9671.22No75.4658.7368.57[^4][^5]

Association between the parameters of CEUS and clinical features of HCC patients {#S0003-S2004}
--------------------------------------------------------------------------------

Based on positive expressions of Sall4, WNT3a and β-catenin protein in HCC tissues, the patients with HCC were divided into positive and negative groups. The results revealed that no significant association was observed between the patients' age, gender and tumor differentiation and the TTP, PI, AUC and WOT (*P*\>0.05), whereas Sall4, WNT3a and β-catenin expression, tumor size, vascular invasion and TNM stage were significantly associated with the TTP, PI, AUC and WOT (*P*\<0.05, [Table 4](#T0004){ref-type="table"}).Table 4Association of quantitative parameters of CEUS with clinicopathological features of HCC patientsFeatureTime to peak (s)Peak intensity (dB)Area under the curve (dB\*s)Washout time (s)Age (years)\<5021.52±4.3360.81±8.44600.18±48.7772.23±12.68≥5022.68±5.2360.62±9.74596.40±33.8876.65±11.82GenderMale22.44±4.5060.74±7.65600.43±54.1573.42±12.20Female22.53±5.2360.62±9.84592.58±49.2274.88±10.72Tumor differentiationLow22.32±5.1260.47±7.18588.45±45.6271.63±12.76Moderate21.86±3.6159.49±9.48590.85±49.2872.75±13.19High22.88±4.6560.74±8.57585.75±45.4772.46±9.07TNM stageI+II24.79±3.4857.53±9.61586.66±38.5771.38±11.46III+IV21.02±3.12\*62.55±8.42\*600.85±41.22\*74.64±12.31\*Tumor size \<3 cm24.26±4.0456.62±9.84578.79±41.0775.31±12.28 ≥3 cm20.53±4.15\*63.73±6.73\*603.24±41.84\*65.23±10.37\*Vascular invasionYes21.34±3.6864.57±8.82606.51±47.7966.52±11.75No24.55±5.44\*55.32±8.58\*575.84±46.28\*74.11±10.41\*Sall4 expressionPositive21.48±5.3265.00±7.29597.45±30.2664.56±11.37Negative25.25±3.34\*53.72±8.27\*573.88±43.73\*74.35±10.46\*WNT3a expressionPositive20.18±5.6163.21±8.37601.34±45.7666.35±11.42Negative24.31±4.23\*54.19±6.98\*576.25±51.28\*75.26±9.62\*β-catenin expressionPositive20.88±4.6363.48±7.60604.92±42.2367.32±11.67Negative24.77±4.22\*54.52±8.24\*578.48±38.26\*73.89±9.18\*[^6][^7]

Association between Sall4, WNT3a and β-catenin expression, and the parameters of CEUS in DFS of HCC patients {#S0003-S2005}
------------------------------------------------------------------------------------------------------------

The HCC patients were divided into 2 groups based on the median of TTP, PI, AUC and WOT (22 s, 60.3 dB, 593.4 dB\*s and 72 s, respectively). We found that the DFS rates were not associated with age and gender, but associated with TNM stage, tumor size, tumor differentiation and vascular invasion, as well as Sall4, WNT3a and β-catenin expression (*P*\<0.05). And the results showed that the HCC patients with positive Sall4, WNT3a and β-catenin expression had significantly low survival rates. In addition, the preoperative TTP, PI, AUC, and WOT were also associated with the DFS rates, suggesting reduced survival rates in patients with short TTP, strong PI, large AUC or short WOT ([Table 5](#T0005){ref-type="table"}). Furthermore, we selected the factors including tumor differentiation, TNM stage, tumor size, vascular invasion, Sall4, WNT3a and β-catenin expression, the parameters of CEUS, including TTP, PI, AUC and WOT for multivariate survival analysis.  We found that tumor differentiation, TNM stage, tumor size, tumor number, vascular invasion, Sall4, WNT3a and β-catenin expressions, and preoperative TTP and PI ([Table 6](#T0006){ref-type="table"}) were significantly correlated with HCC, indicating that Sall4, WNT3a and β-catenin expressions and preoperative TTP and PI are the independent prognostic factors for HCC patients.Table 5Univariate survival analysis of risk factors for the prognosis of HCC patientsFactor1-year DFS rate (%)3-year DFS rate (%)5-year DFS rate (%)Age (years)\<5066.5354.3830.12\>5064.7455.4731.34GenderMale65.5052.3231.53Female65.4256.5230.28Tumor differentiationLow53.24\*33.13\*10.42\*Moderate65.56\*46.16\*21.16\*High86.3563.3548.85TNM stageI+II88.6380.2841.24III+IV56.32\*31.06\*18.21\*Tumor size \<3 cm87.5364.6338.27 \>3 cm54.75\*37.64\*19.42\*Vascular invasionYes54.3232.1920.14No77.43\*65.21\*37.26\*SALL4 expressionPositive51.0830.2116.43Negative83.21\*68.74\*40.89\*WNT3a expressionPositive56.4540.0722.13Negative82.34\*63.52\*33.54\*β-catenin expressionPositive57.3241.2323.15Negative81.21\*58.94\*31.72\*Time to peakShort54.2241.3621.17Long79.45\*60.29\*34.34\*Peak intensityStrong54.2241.3621.17Weak79.45\*60.29\*34.34\*Area under the curveSmall79.4560.2934.34Large54.22\*41.36\*21.17\*Washout timeLong79.4560.2934.34Short54.22\*41.36\*21.17\*[^8][^9] Table 6Multivariate survival analysis with Cox proportional hazards model of risk factors for the prognosis of HCC patientsFactorRisk95% CI*P*-valueTumor differentiation0.1180.123--0.225\<0.001TNM stage20.6688.632--30.746\<0.001Tumor size6.8213.546--13.126\<0.001Vascular invasion4.6232.673--6.3410.001Sall4 expression9.5687.352--20.8740.002WNT3a expression5.2432.365--10.1680.014β-catenin expression3.0321.625--6.8320.032Time to peak2.0641.435--2.3410.033Peak intensity1.6581.372--3.2120.042Area under the curve0.8320.767--1.4310.074Washout time0.8780.885--1.3520.083[^10]

Discussion {#S0004}
==========

In this study, we found that the mRNA and protein expression of Sall4, WNT3a and β-catenin in the HCC tissues were significantly upregulated compared with the adjacent tissues. Upregulation of these proteins was associated with tumor differentiation, TNM stage, tumor size, vascular invasion and liver cirrhosis of HCC patients. In addition, we found that decreased TTP and WOT and increased PI and AUC of CEUS in the HCC were also correlated with TNM stage, tumor size and vascular invasion. In addition, Sall4, WNT3a and β-catenin protein were significantly associated with the TTP, PI, AUC and WOT. Collectively, our study supported that combination of Sall4/Wnt/β-catenin signaling with CEUS may become a useful supplementary method for HCC patients early diagnosis.

Sall4 is highly expressed in various cancers, including gastric cancer, breast cancer, lung cancer, colorectal cancer and HCC.[@CIT0014]--[@CIT0016] Sall4 silencing by RNA interference or Sall4 peptide inhibitor treatment led to impaired lung cancer cell growth through EGFR and IGF1R signaling pathways.[@CIT0017] Sall4 exhibits its oncogenic roles in gastric cancer progression through directly activating CD44 expression.[@CIT0018] High Sall4 expression levels were associated with low overall survival, event-free survival and the presence of metastasis in hepatoblastoma, suggesting Sall4 is an independent prognostic predictor for overall survival.[@CIT0019] In line with our results in this study, Hao et al found that Sall4 expression positively correlated with lymph node metastasis and TNM stages in colorectal cancer; and β-catenin was expressed significantly higher in colorectal cancer than normal tissue. The patients with colorectal cancer of co-expression of these two molecules showed advanced lymph node metastasis and TNM stage.[@CIT0020] Co-location of Sall4 and β-catenin was found in the nucleus and cytoplasm, which indicated that the function of Sall4 in promoting lymph node metastasis and advanced clinical stage might partly be due to the interaction with β-catenin.[@CIT0020] Sall4 modulates the stemness of ESCC cells via Wnt/β-catenin signaling pathway and in EMT.[@CIT0010] And Sall4 promotes intrahepatic cholangiocarcinoma cell proliferation by activating Wnt/β-catenin signaling.[@CIT0011]

Interestingly, Sall4, WNT3a and β-catenin protein were significantly associated with the TTP, PI, AUC and WOT evaluated by CEUS. CEUS can be used to observe the neovessels in tumors. The parameters of CEUS reflect the proportions between the portal veins and hepatic arteries, and the vascular structures in tumors.[@CIT0021] PI and AUC of CEUS can estimate enhancement intensity, and the TTP and WOT of CEUS are used to evaluate enhancement time.[@CIT0022] PI and AUC of CEUS are applied to reveal the intratumoral vascularity of ovarian tumors as noninvasive parameters.[@CIT0023] Tian and Wang showed that the PI and AUC of poor-differentiated HCC lesions were significantly lower than those of well-differentiated HCC lesions.[@CIT0024] Our findings showed that decreased TTP and WOT and increased PI and AUC of CEUS in HCC lesions were correlated with TNM stage, tumor size and vascular invasion. Besides, the preoperative TTP, PI, AUC and WOT were associated with the DFS rates, suggesting reduced survival rates in patients with short TTP, strong PI, large AUC or short WOT. Additionally, this study first time found that Sall4/Wnt/β-catenin expression was associated with TTP, PI, AUC and WOT in patients with HCC. Thus, combination CEUS and Sall4/Wnt/β-catenin signaling can more accurately evaluate the intratumoral neovascular generation and prognosis of HCC patients.

Conclusion {#S0005}
==========

This study suggests that combination quantitative parameters of CEUS and Sall4/Wnt/β-catenin signaling may be a useful supplementary method for early screening and diagnosis in HCC patients. And a larger cohort is needed in the future to confirm our results study and provide strong evidence for predicting prognosis of patients with HCC.
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[^1]: **Abbreviations:** AFP, alpha-fetoprotein; HBsAg/HCV, hepatitis B surface antigen/hepatitis C virus; HBV-DNA, hepatitis B virus-DNA.

[^2]: **Note:** \**P*\<0.05 compared with the adjacent normal tissues.

[^3]: **Abbreviations:** CEUS, contrast-enhanced ultrasound; HCC, hepatocellular carcinoma.

[^4]: **Notes:** *P*-value was calculated by Chi-square test.

[^5]: **Abbreviations:** Sall4, Sall4, Spalt-Like Transcription Factor 4; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HBV, hepatitis B virus.

[^6]: **Note:** *\*P*\<0.05 of comparison within group.

[^7]: **Abbreviations:** Sall4, Spalt-Like Transcription Factor 4; HCC, hepatocellular carcinoma.

[^8]: **Note:** \**P*\<0.05 of comparison within group.
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